• Januvia Medical Record Review & Outsourcing Services

Januvia (Sitagliptin) is an oral antidiabetic medicine belonging to class dipeptidyl peptidase-4 (DPP-4) inhibitor, manufactured by Merck & Co.,  was approved by the U.S. Food and Drug Administration (FDA) in 2006. In 2007, the FDA approved a variation of Januvia called Janumet, which is a combination of sitagliptin and metformin and is also made by Merck.

Sitagliptin is an anti-diabetic drug that works by increasing the levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. It works by regulating the levels of insulin your body produces after eating.

Serious Alleged Injuries may include:

  • Pancreatic Cancer
  • Thyroid Cancer
  • Acute Pancreatitis
  • Hemorrhagic Pancreatitis
  • Necrotizing Pancreatitis
  • Severe Joint Ache

FDA Safety Warnings:

In 2011, the FDA received almost 200 reports of acute and chronic pancreatitis linked to Januvia some of which were fatal. In 2015, the FDA warned Januvia (and Janumet) could cause severe joint pain. The most serious injuries associated with Januvia are acute pancreatitis, pancreatic cancer, and thyroid cancer.

In June 2015, the FDA warned that the type 2 diabetes medicines Sitagliptin (and saxagliptin, linagliptin, and alogliptin) may cause joint pain, which can be severe and disabling. The FDA has added a new Warning and Precaution about this risk to the labels of all medicines in the DPP-4 inhibitors.

Legal Updates:

Lawsuits against the makers of Type 2 diabetes drugs Januvia and others were consolidated in MDL No. 2452 in California federal court. Allegations include that the drug manufacturers failed to warn about the risk of pancreatic cancer and pancreatitis.

In November 2015, Judge Anthony J. Battaglia under a motion called summary judgment granted the manufacturer’s request to dismiss all the cases in the MDL. AT this time 749 cases were pending in the MDL.

In September 2016, plaintiff’s attorneys filed an appeal on behalf of the MDL, stating that Battaglia misinterpreted the U.S. Supreme Court preemption law.

The Ninth Circuit has not yet returned the decision. The count of cases as of April 15, 2017, was near to 1000. Thus, the fate of the plaintiffs is now in the hand of U.S. Court of Appeals for the Ninth Circuit.

The lawsuits were reinstated on appeal in November 2017, by the United States Court of Appeals for the Ninth Circuit. Jurisdiction returned to U.S. District Court for the Southern District of California on January 2, 2018.


  • Usage of Januvia
  • Duration of Usage
  • Indication of Usage in Medical and Pharmacy Records
  • Complications and their treatment after intake

Medical Record Review and claim validation of Januvia case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.



Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...


NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...



CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...


CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...


NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

Rewards & Recognition Program - July 2019
Neural IT organized ‘Rewards & Recognition Program' on July 5, 2019, to motivate employees an
International Yoga Day - Image - Neural IT
International Yoga Day celebrated at Neural IT to bring physical and emotional health for our tea
MTMP April 2019
Neural IT shared presence with Mike Papantonio at the spectacular 3-day conferenc

Latest Tweets